Agfa to launch Impax for Nuclear Medicine at EANM 2011

Lisa Fratt | | Health Imaging | Diagnostic Imaging
Agfa HealthCare will present Impax for Nuclear Medicine at the 2011 Congress of the European Association of Nuclear Medicine (EANM) in Birmingham, England.

Impax for Nuclear Medicine supports exam flow from order entry to the final distribution of nuclear medicine results. The PACS includes functionalities to process, read and report nuclear medicine, SPECT, PET and multimodality images from a workstation, according to Mortsel, Belgium-based Agfa. Images and diagnoses can be shared with referring physicians within or outside the hospital walls.

Impax for Nuclear Medicine includes Oasis for Impax, developed in collaboration with Segami. Oasis brings a nuclear medicine image processing and viewing package to the workstation. 

Lisa Fratt

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.